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of complementary and alternative medicines for treating 
the mentioned disease. 
Ficus bengalensis Linn. (Family: Moraceae) is a reputed plant 
in ayurvedic medicine and commonly known as ‘banayan 
tree’ in ayurvedic literature. Milky juice from stem, seed, 
or fruits of the plant is applied externally in rheumatism 
and to the soles of feet when inflamed, internally used 
in dysentery and diarrhea.[3] All the parts of the plant 
have astringent, anti-inflammatory, antiarthritis, and 
antidiarrheal activities. The bark is also used in diarrhea 
and dysentery. Latex is useful in hemorrhage, diarrhea, and 
dysentery, as well as in hemorrhoid and inflammation.  [4] 
Severe inflammation and diarrhea are the characteristics 
of IBD. So, with the light of the folkloric usage of the 
bark mainly in inflammation and diarrhea, this study 
INTRODUCTION
Inflammatory bowel disease (IBD) encompasses many 
chronic, relapsing inflammatory disorders involving 
the gastrointestinal tract.[1] There are two primary types 
of IBD, namely Crohn’s disease and ulcerative colitis. 
In IBD, the intestine (bowel) becomes inflamed, often 
causing recurring abdominal cramps, and diarrhea. 
Among the pathological findings associated with IBD 
are increases in certain inflammatory mediators, signs 
of oxidative stress, a deranged colonic milieu, abnormal 
glycosaminoglycan content of the mucosa, increased 
intestinal permeability, increased sulfide production, and 
decreased methylation.  [2] The available treatment choices 
have major limits owing to associated adverse effects and 
compliance issues.[1] As a result, there is high prevalence 
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The present study was designed to evaluate the effects of aqueous extract of Ficus bengalensis Linn. bark 
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carried out to evaluate the efficacy of the aqueous extract 
of F. bengalensis bark (AEFB) in IBD.
MATERIALS AND METHODS
Plant materials
The stem bark of F. bengalensis Linn. was collected from south 
Gujarat region. The plant was identified and authenticated 
by Department of Bioscience, VNSGU, Gujarat, India 
(Voucher specimen number is HMG/0404/2007).
Preparation of plant extract
The stem bark of the plant was air dried, reduced to coarse 
powder, macerated with distilled water for 48 h, filtered 
and the filtrate was evaporated under reduce pressure to 
obtain dry extract (aqueous extractive value 4.8% w/w). 
The extract was stored in cool and dry place and was 
used for pharmacological evaluation. The extract was 
suspended in 0.5% carboxyl methylcellulose (CMC) prior 
to administration. Various phytoconstituents qualitatively 
were determined in aqueous extract according to Wagner 
and Bladt, 1996.[5]
Animals
Adult albino (Wistar strain) rats of either sex weighing 
between 200 and 250 g housed in standard conditions of 
temperature (22 ± 2°C), relative humidity (55 ± 5%), and 
light (12 h light/dark cycles) were used. They were fed 
with standard pellet diet and water ad libitum. Animals were 
approved by the Institutional Animal Ethics Committee 
(IAEC) according to the regulation of Committee for the 
Purpose of Control and Supervision of Experiments on 
Animals (CPCSEA). Throughout the experiments, animals 
were handled according to the suggested ethical guideline 
for the care of laboratory animals.
Chemicals
TNBS (2,4,6-trinitrobenzenesulfonic acid), prednisolone, 
compound 48/80 were bought from the Sigma-Aldrich 
Chemical Co., USA and all other chemicals were purchased 
from the Himedia Pvt. Ltd, India. Biochemicals kits were 
purchased from the Span Diagnostic Ltd, Surat, India.
Acute toxicity testing
Albino rats of either sex weighing 230-240 g selected by the 
random sampling technique were used in the study. Acute 
oral toxicity study was performed as per Organisation for 
Economic Co-operation and Development (OECD)---423 
guideline. The animals were fasted overnight, provided 
only water, after which the aqueous extract of F. benglensis 
(AEFB) was administered to respective groups orally at the 
dose level of 5 mg/kg body weight by gastric intubation 
and the groups were observed for 14 days. If mortality 
was observed in two or three animals, then the dose 
administered was assigned as a toxic dose. If mortality was 
observed in one animal, then the same dose was repeated 
again to confirm the toxic dose. If mortality was not 
observed, the procedure was repeated for further higher 
dose such as 50, 300, and 2000 mg/kg body weight. The 
animals were observed for toxic symptoms such as behavior 
changes, locomotion, convulsion, and mortality for 72 h.
Experimental protocol
The study comprised five different groups of six animals 
each as follows:[6]
•  Control: Saline treated;
•  Model: TNBS (2, 4, 6-trinitrobenzenesulfonic acid, 
0.25 ml, 120 mg/ml in 50% ethanol, intrarectally) on 
first day only;
•  Prednisolone: TNBS (0.25 ml, 120 mg/ml in 50% 
ethanol, intrarectally), on 1st day only and prednisolone 
(2 mg/kg, p.o.) treatment continued till 21st day;
•  AEFB (250 mg/kg): TNBS (0.25 ml, 120 mg/ml in 
50% ethanol, intrarectally) on 1st day only + AEFB 
(250 mg/kg, p.o.) treatment continued till 21st day;
•  AEFB (500 mg/kg): TNBS (0.25 ml, 120 mg/ml in 
50% ethanol, intrarectally) on 1st day only + AEFB 
(500 mg/kg, p.o.) treatment continued till 21st day.
TNBS was delivered by a Teflon cannula (outside 
diameter 1.2 mm, inserted 8 cm) through the anus of 
each rat. Ethanol evokes an acute inflammatory response 
that resolves spontaneously after 1 week. Therefore, we 
preferred to include a saline-treated group as a negative 
control instead of an ethanol-treated group. Various 
physical parameters like body weight, food intake, and 
water intake were measured on 1st and 21st days. On 21st 
day, animals were sacrificed by cervical dislocation and 
dissected open to remove GIT (from stomach to anus). 
GIT was flushed gently with saline and cut open. Weight of 
the colon taken was measured and then the colon mucosa 
damage index (CMDI) and the histopathological score i.e. 
disease activity index (DAI) were evaluated. Colon samples 
were taken for determinations of myeloperoxidase (MPO) 
and superoxide dismutase (SOD) activity, malondialdehyde 
(MDA) and nitric oxide (NO) content level. The percentage 
protection of the mast cell degranulation in the mesentery 
of intestine of the rat was also measured.
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Assessment of the colon mucosa damage index 
(CMDI)
The colon segment taken 10 cm proximal to anus of the 
sacrificed rats was excised longitudinally, was rinsed with 
saline buffer, and fixed on a wax block. Each colon was 
observed and evaluated by two independent observers. 
Macroscopic scoring was done evaluated according to 
the formula of CMDI reported by Wei et al. 2003.[7] 
Briefly describe as follows: (1) 0-normal mucosa, 1-mild 
hyperemia, no erosion or ulcer on the mucosal surface, (2) 
2-moderate hyperemia, erosion appearing on the mucosal 
surface, (3) 3-severe hyperemia, necrosis, and ulcer on the 
mucosal surface with the major ulcerative area extending 
<40%, (4) 4-severe hyperemia, necrosis, and ulcer on the 
mucosal surface with the major ulcerative area extending 
>40%.
Assessment of disease activity index (DAI)
The colon tissue samples taken for histology were fixed 
overnight in 4% neutral buffered formalin, processed, 
sectioned (4 μm thick), and stained with hematoxylin and 
eosin. Each colon sample was observed and evaluated by 
two independent observers. To assess, the histopathological 
score was assessed according to the modified model of 
the system reference given by Wei et al. 2003 which are 
as follows: (1) the infiltration of acute inflammatory 
cells: 0-no, 1-mild increasing, 2-severe increasing; (2) the 
infiltration of chronic inflammatory cells: 0-no, 1-mild 
increasing, 2-severe increasing; (3) the deposition of 
fibrotin protein: 0-negative, 1-positive; (4) the submucosa 
edema: 0-no, 1-patchy-like, 2 fusion-like; (5) the epithelium 
necrosis: 0-no, 1-limiting, 2-widening; (6) the epithelium 
ulcer: 0-negative, 1-positive.
Determination of the MPO, SOD activity and MDA, 
NO content in the colon
The colon sample was homogenized (50 gm/L) in 50 
mmol/l ice-cold potassium phosphate buffer (pH 6.0) 
containing 0.5% of hexadecyltrimethylammonium 
bromide. The homogenate was first frozen and thawed 
thrice for three times, and then centrifuged at 4000 rpm 
for 20 min at 4°C for the measurement of myelopeoxidase 
(MPO) activity. MPO, a marker of neutrophil migration 
was estimated by measuring H2O2-dependent oxidation 
of O dianisidine.[8]
For the determination of SOD activity and MDA, NO 
contents, the colon sample was homogenized in ice-cold 
phosphate buffer saline (pH 7.4) and centrifuged at 3000 
rpm for 10 min at 4°C. The clear supernatant was used 
for the assay of MDA which is the indicator of lipid 
peroxidation,[9] and the endogenous antioxidant enzyme 
SOD was estimated according to Misra and Fridovich, 
1972.[10] 
NO was determined according to the method of Yamamoto 
et al.[11] NO is produced by Nitric oxide synthatase (NOS). 
NOS convert arginine to citruline, during this reaction NO 
is produced. NO reacts with N-1-napthylethylenediamine 
dihydrochloride and sulphanilamide to give azo compound. 
The color intensity of that azo compound was measured 
at 540 nm. The quantity was measured by standard curve 
and reported as nmoles/mg protein. 
% Mesenteric mast cell protection
% Mast cell protection is suggested by a decrease in the 
degranulation of the mast cell. Mesentery of intestine 
from obtained the animals was removed and placed in the 
Ringer Locke solution (NaCl 0.9%, KCI 0.042%, CaCl2 
0.024%, NaHCO3 0.015%, and dextrose 0.1%). Then it 
was stained and fixed with the 4% formaldehyde containing 
0.1% toluidine blue. %Mast cell protection was evaluated 
microscopically at 40 magnification.[12]
Statistical analysis
Data obtained from the animal experiments were expressed 
as the mean ± SEM of six observations. The statistical 
difference was evaluated by one-way ANOVA. Differences 
were accepted as statistically significant when P<0.05.
RESULTS
The yield of AEFB was estimated to be 4.8% w/w and 
preliminary phytochemical analysis showed that it contained 
presentation of glycosides, carbohydrates, flavonoids, 
triterpenoids, tannins, and phenolic compounds. No 
mortality and the sign of toxicity observed at the dose of 
5000 mg/kg.
Changes in the physical parameters
On 1st and 21st days, changes in the physical parameters 
including body weight, food intake, and water intake 
were measured. When compared with the control group, 
significant reductions in all these parameters were observed 
with the model group. While, however, in the animals 
treated with prednisolone and AEFB had no significant 
reduction in the body weight, food intake and water intake 
compared to the model group [Table 1]. However, in 
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contrast, the weight of the colon was increased significantly 
in the TNBS-treated group i.e. model group compared 
to the normal group but it significantly decreased in the 
prednisolone- and AEFB-treated groups compared to the 
model group [Figure 1].
Inflammatory changes in the mucosa of colon
The main parameters used for evaluating the degree of 
colonic inflammation in IBD were CMDI, DAI, and MPO 
activities. In this study, significant differences in CMDI, 
DAI, and MPO activities were found, when compared 
with that of normal and model groups. In prednisolone- 
and AEFB-treated groups CMDI and DAI- and MPO 
activities significantly decreased when compared with the 
model group [Table 2].
Oxidative changes in the colon
Severe oxidative stress induced by intrarectal administration 
of TNBS was shown by significant elevation of MDA and 
NO level and a significantly decrease in the SOD activity 
compared to the control group. After treatment with 
prednisolone and AEFB, there was a significant decrease 
both in MDA and NO levels and an increase in the SOD 
activity when compared with the model group, which 
showed that they have antioxidant properties [Table 3].
Mesenteric mast cell degranulation
In the animals treated with the TNBS, i.e. model group, a 
significant increase in the mast cell degranulation occurred 
compared with the normal group. Treatment of the 
prednisolone and AEFB significantly decreased the mast 
cell degranulation that was significantly lower than that in 
of TNBS-treated animals [Table 3].
Histopathological changes in the colon
Histopathological analysis of the colon in TNBS-treated 
group clearly showed that there were severe hyperplasia, 
edema, infiltration of inflammatory cells particularly 
neutrophils and lymphocytes, necrosis and ulcer on the 
mucosal surface >40% showing the progression to severe 
Table 1: Effect of aqueous extract of Ficus bengalensis on water intake, food intake, and body weight in TNBS-
induced inflammatory bowel disease in rats
Groups Reduction in body weight (g) Reduction in food intake  
(g/group)
Reduction in water intake  
(ml/group)
Control 7 ± 1 5 ± 0.8 5 ± 1.8
Model  50 ± 2.5* 50 ± 4* 65 ± 1.2*
Prednisolone  10 ± 2# 6 ± 1.1# 5 ± 2#
AEFB (250 mg/kg)  15 ± 0.9# 10 ± 1# 9 ± 1.1#
AEFB (500 mg/kg)  13 ± 1# 8 ± 0.9# 7 ± 2.1#
Each value presented as mean ± SEM (n=6) (one-way ANOVA). *Compared with control group, P < 0.001 #Compared with model group, P < 0.001 
Table 2: Effects of aqueous extract of Ficus bengalensis on CMDI, DAI, and MPO activity in the colon tissue of TNBS-
induced inflammatory bowel disease in rats
Groups CMDI DAI MPO
(unit/mg of protein)
Control 0.0 ± 0.0 0.7 ± 0.11 22 ± 0.9
Model  6.1 ± 0.31* 8.3 ± 0.2* 88 ±2.5*
Prednisolone  1.4 ± 0.21# 3.2 ± 0.10# 28 ±1.2#
AEFB (250 mg/kg)  2.5 ± 0.13# 4 ± 0.13# 40 ±15##
AEFB (500 mg/kg)  1.8 ± 0.18# 2.2 ± 0.11# 38 ±1.8##
(CMDI: colonic mucosal damage index, DAI: disease activity index, MPO: myeloperoxidase). Each value presented as mean ± SEM (n=6) (one-way ANOVA). *When compared 
to control group P<0.001,
#
When compared to model group P<0.001. ##When compared to model group P<0.01. 
Table 3: Effect of aqueous extract of Ficus bengalensis on MDA and NO content, SOD activity and mast cell 
degranulation in TNBS-induce inflammatory bowel disease in rats
Groups MDA  
(nmole/mg of protein)
NO  
(nmole/mg of protein)
SOD  
(U/min/mg of protein)
Mast cell degranulation 
(% protection)
Control  17 ± 0.7 12 ± 0.5 0.89 ± 0.05 80 ± 1.5
Model  88 ± 2.1* 28 ± 1.1* 0.22 ± 0.03* 8 ± 0.5*
Prednisolone  34 ± 1.4# 14 ± 0.8# 0.78 ± 0.05# 62 ± 1.0#
AEFB (250 mg/kg)  50 ± 1.7# 20 ± 0.5# 0.7 ± 0.02# 45 ± 0.8#
AEFB (500 mg/kg)  38 ± 1.8# 16 ± 0.6# 0.62 ± 0.03# 54 ± 0.9#
(MDA: malondialdehyde, NO: nitric oxide, SOD: superoxide dismutase), Each value presented as mean ± SEM (n=6) (one-way ANOVA). Compared with the control group 
P<0.001, #Compared with the model group P<0.001. 
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disease [Figure 2B] compared to control group [Figure 
2A]. Animals treated with the prednisolone showed mild 
hyperplesia and edema, infiltration of inflammatory 
cells was also decreased, normal mucosa, no necrosis, 
and no ulceration were observed [Figure 2C]. With the 
treatment with of AEFB, the progression of IBD were 
less prominent which was characterized by a decreased in 
hyperplasia and edema, also a declined in the infiltration 
of the inflammatory cells, in addition, mild necrosis, and 
ulceration were present in AEFB 250 mg/kg group [Figure 
2D] but absent in AEFB 500 mg/kg group [Figure 2E].
DISCUSSION
TNBS is a hapten compound, and when it is bound with 
a substance of high molecular tissue proteins, it will turn 
into an antigen. It has shown that it can elicit immunologic 
responses; induce generation of inflammatory bowel 
disease (IBD).[12,13] This model shares many of the 
histopathological and clinical features of human IBD and 
is useful for the study of the etiopathogenesis of chronic 
colon inflammation as well as providing an inexpensive 
model suitable for assessing therapeutic agents. 
In IBD body weight, food intake and water intake are the 
important indicators of the severity of this disease. As 
there is a severe inflammation in the colon, the tolerability 
to the food and water decreases, therefore body weight is 
also decreased.[14] In our study we found that the treatment 
with AEFB decreased the weight loss by improving the 
tolerability to food and water intake. AEFB improved all 
these physical parameters that were comparable to that of 
prednisolone.
In IBD, weight of colon is increased due to severe 
inflammation and edema.[15] Animal treated with 
TNBS showed high colon weight compare to normal 
animals. Treatment with AEFB reduced colon weight of 
animals treated with TNBS. That shows AEFB reduced 
inflammation and edema.
In our study, we induced IBD by intrarectal administration 
of TNBS in animals. The severity of colonic inflammation 
in developed disease was evaluated by measuring main 
parameters CMDI and DAI scores and MPO activity. In 
present study, we found that decreased in progression 
of the disease pathogenesis following treatment with 
AEFB characterized by significantly declined in the 
score of CMDI and DAI compared to the model 
group which is also supported by the changes in the 
histopathology of the colon. MPO is an enzyme found 
in the neutrophils, and can be used as a quantitative index 
of inflammation in colonic tissue. MPO activity may be 
Figure 1: Effect of aqueous extract of Ficus bengalensis on the weight 
of the colon in TNBS-induced inflammatory bowel disease in rats. 
*When compared to control P<0.001, #When compared to model 
P<0.001, $When compared to model P<0.01. One-way ANOVA (n=6)
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Figure 2: Effect of aqueous extract of Ficus bengalensis on tissue 
histopathology in TNBS-induced inflammatory bowel disease in rat. 
Control group: shows normal mucosa (A), model group: shows severe 
hyperplasia, ulcer appearing on the mucosal surface with the major 
ulcerative area extending >40% (B), prednisolone: shows moderate 
hyperplasia, no erosions appear on the mucosal surface (C), AEFB (250 
mg/kg): shows mild hyperplasia and erosion appear on the mucosal 
surface (D), AEFB (500 mg/kg): mild hyperplasia, no ulceration on 
mucosa (E).
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regarded as an index of inflammation damage. The main 
pathological feature of IBD is transmural infiltration of 
polymorphonuclear neutrophils and MPO is released from 
these neutrophils.  [16,17] Treatment with AEFB significantly 
decreased the level of MPO compared to the model group 
which shows that AEFB decreases the infiltration of the 
inflammatory cells which are responsible for the increasing 
the progression of the disease condition. 
Many studies have revealed that the increase of oxidative 
stress and iNOS activity was a notable feature of IBD, 
which resulted in a pathological cascade of free radical 
reactions and further yielding more oxidative free 
radicals. Failures of the endogenous antioxidant defense 
mechanisms promote formation of excessive free radicals 
and consequent tissue damage.[18] Parameters such as 
MDA, NO content, and SOD activity can be indicative 
of oxidative stress status of the disease. MDA level 
can be determining by the thiobarbituric acid reacting 
substance (TBARS). As observed in our study, the 
increase in MDA levels in the colon affected by the TNBS 
administration suggests enhanced lipid peroxidation that 
could be responsible for the tissue damage. Many studies 
have reported that increased iNOS activity yielded more 
oxidative free radicals such as peroxynitrite (ONOO−) to 
impair the structure and function of the cells.[19] Excess of 
NO is responsible for the increase in the disease severity 
by increasing vascular permeability and decrease in the 
antioxidant defense mechanism by inhibiting the SOD 
enzyme. We made an attempt to measure the NO by means 
of Griess assay which relies on a diazotization reaction.  [11] 
SOD is an important endogenous antioxidant enzyme 
which prevents the production of free radicals.[20] 
In the present study, in the animal group treated with 
TNBS there was observed an increase in the oxidative 
stress indicated by the higher MDA and NO level and 
as well as a decrease in the SOD activity which are 
responsible for the tissue damage and development of 
inflammation. In our study we found that for the animals 
treated with AEFB, both the MDA and NO levels were 
significantly decreased and SOD activity was significantly 
increased which confirmed that AEFB decreased the tissue 
damage and inflammation which suggested its significant 
antioxidant property.
Mast cell degranulation causes mucus secretion, mucosal 
edema, increased gut permeability, and release of various 
inflammatory mediators which may be responsible for 
some of the signs and symptoms of inflammatory bowel 
disease.[21] In our study a significant rise in the mast cell 
degranulation was observed in the TNBS-treated animals, 
while in AEFB-treated animals, mast cell degranulation was 
significantly lower. This observation clearly indicates that 
AEFB provides the protection against the injury produced 
by inflammatory mediators released from the mast cell 
degranulation by stabilizing it them. Prednisolone at a 
dose of 2 mg/kg and AEFB at doses of 250 mg/kg and 
500 mg/kg also provided the protection against TNBS-
induced IBD in rats. The AEFB protection by in the IBD 
was comparable to that of prednisolone. Therefore, it may 
be possible might be postulated that AEFB produced this 
protection by the same mechanism that of prednisolone 
i.e. inhibition of the infiltration of the inflammatory cells, 
antioxidant activity and decrease in the synthesis of the 
inflammatory mediators.
Various phytochemicals like phenolic compounds and 
flavonoids present in AEFB may be responsible for its 
antioxidant effect. Flavonoids also have mast cell stabilizing 
property.[22,23] Terpenoids[24] and flavonoids[25] have an anti-
inflammatory effect, which may be responsible for the anti-
inflammatory effect of AEFB in IBD. Due to the presence 
of flavonoids and terpenoids in the bark of Ficus bengalensis 
and the results obtained in this study might be used in to 
the bark of the title plant might be used for the treatment 
of inflammatory bowel disease.
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